Abstract
A 39-year-old woman received a 10-day treatment with muromonab-CD3 (Orthoclone OKT3) (total dose 50 mg) as part of a clinical trial designed to test its efficacy in the treatment of multiple sclerosis. The patient concomitantly received methylprednisolone (Solu-Medrol), 50 mg on the first day of treatment, and indomethacin, 50 mg, three times daily throughout the 10-day course. She had had psoriasis vulgaris for 18 years, which was largely confined to extensor surfaces of her arms and legs. She had received intermittent treatment with topical coal tar preparations in the past without benefit. The condition
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
